Renal dysfunction improves risk stratification and may call for a change in the management of intermediate- and high-risk acute pulmonary embolism: results from a multicenter cohort study with external validation
Open Access
- 9 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 25 (1), 1-11
- https://doi.org/10.1186/s13054-021-03458-z
Abstract
Background: Renal dysfunction influences outcomes after pulmonary embolism (PE). We aimed to determine the incremental value of adding renal dysfunction, defined by estimated glomerular filtration rate (eGFR), on top of the European Society of Cardiology (ESC) prognostic model, for the prediction of 30-day mortality in acute PE patients, which in turn could lead to the optimization of acute PE management. Methods: We performed a multicenter, non-interventional retrospective post hoc analysis based on a prospectively collected cohort including consecutive confirmed acute PE stratified per ESC guidelines. We first identified which of three eGFR formulae most accurately predicted death. Changes in global model fit, discrimination, calibration and reclassification parameters were evaluated with the addition of eGFR to the prognostic model. Results: Among 1943 patients (mean age 67.3 (17.1), 50.4% women), 107 (5.5%) had died at 30 days. The 4-variable Modification of Diet in Renal Disease (eGFRMDRD4) formula predicted death most accurately. In total, 477 patients (24.5%) had eGFRMDRD4 < 60 ml/min. Observed mortality was higher for intermediate–low-risk and high-risk PE in patients with versus without renal dysfunction. The addition of eGFRMDRD4 information improved model fit, discriminatory capacity, and calibration of the ESC model. Reclassification parameters were significantly increased, yielding 18% reclassification of predicted mortality (p < 0.001). Predicted mortality reclassifications across risk categories were as follows: 63.1% from intermediate–low risk to eGFR-defined intermediate–high risk, 15.8% from intermediate–high risk to eGFR-defined intermediate–low risk, and 21.0% from intermediate–high risk to eGFR-defined high risk. External validation in a cohort of 14,234 eligible patients from the RIETE registry confirmed our findings with a significant improvement of Harrell’s C index and reclassification parameters. Conclusion: The addition of eGFRMDRD4-derived renal dysfunction on top of the prognostic algorithm led to risk reclassification within the intermediate- and high-risk PE categories. The impact of risk stratification integrating renal dysfunction on therapeutic management for acute PE requires further studies.Keywords
Funding Information
- BMS-Pfizer
- Bayer Healthcare SAS
This publication has 32 references indexed in Scilit:
- The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not RevolutionClinical Chemistry, 2013
- Association of Mild to Moderate Chronic Kidney Disease With Venous ThromboembolismCirculation, 2012
- A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival dataStatistics in Medicine, 2012
- Intracerebral Hemorrhage with Thrombolytic Therapy for Acute Pulmonary EmbolismAmerican Journal Of Medicine, 2012
- Outpatient treatment in patients with acute pulmonary embolism: the Hestia StudyJournal of Thrombosis and Haemostasis, 2011
- Performance of reclassification statistics in comparing risk prediction modelsBiometrical Journal, 2011
- Performance of the Cockcroft-Gault, MDRD, and New CKD-EPI Formulas in Relation to GFR, Age, and Body SizeClinical Journal of the American Society of Nephrology, 2010
- Assessment of renal dysfunction improves troponin‐based short‐term prognosis in patients with acute symptomatic pulmonary embolismJournal of Thrombosis and Haemostasis, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) StatementEpidemiology, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005